Results 251 to 260 of about 20,131,715 (394)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Evaluation of Hematological, Biochemical, and Coagulation Tests in Patients with Hepatitis C. [PDF]

Medicina (Kaunas)
Janulaityte I, Petkute G, Maciuliene A, Borodiciene J, Kareiva J, Vitkauskiene A.   +5 more
europepmc   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, EarlyView.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

Usefulness of the Fibrosis-3 index in patients with hepatitis C. [PDF]

Ann Med Surg (Lond)
Kariyama K, Toyoda H, Kumada T, Yasuda S, Shiota S, Wakuta A, Nouso K.   +6 more
europepmc   +1 more source

Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C

, 2016
Taylor Aiken, Ari Garber, Dawn Thomas, Nicole Hamon, Rocío López, Venkata Rajesh Konjeti, Arthur J. McCullough, Nizar N. Zein, John J. Fung, Medhat Askar, Binu V. John   +10 more
openalex   +2 more sources

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Hepatitis C Co-infection Among Pregnant Women With Syphilis in West Virginia, 2019-2023. [PDF]

Open Forum Infect Dis
Hudson AG, Huff B, Boote J, Pack K, Watkins M, White H, Wilson S, McBee S.   +7 more
europepmc   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Hepatitis C virus-associated cardiomyopathy: A review of pathogenesis. [PDF]

World J Virol
Bharaj IS, Singh G, Brar AS, Kacheria A, Kahlon J, Mohmand B, Sohal A, Yeneneh BT.   +7 more
europepmc   +1 more source

Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era

Journal of Viral Hepatitis, 2018
O. Falade-Nwulia, M. Sulkowski, A. Merkow, C. Latkin, S. Mehta   +4 more
semanticscholar   +1 more source